Recent Updates
Recently added Catalysts
CLDI Neutral Sentiment

Scientific Advisory Board Member Interview – Santosh Kesari, M.D./Ph.D.

Saturday, February 3, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article features an interview with Santosh Kesari, M.D./Ph.D., a member of the Scientific Advisory Board. It is part of a series of interviews with advisory board members, showcasing their insights and contributions. The article does not provide specific details about the interview content or topics discussed.
Price reaction · baseline $95.988 (2024-02-02 close) · hit after-hours · clean, no other CLDI news in the window
day 0 close
-6.3%
day 1
-2.9%
day 3 · peak
-26%

Market Sentiment Analysis

Full Press Release Details

Scientific Advisory Board Member Interview – Santosh Kesari, M.D./Ph.D. Interviews & Media February 3, 2024 Next Post Scientific Advisory Board Member Interview – W.K. Alfred Yung, M.D. Previous Post Scientific Advisory Board Member Interview – Bernard Fox, Ph.D.
ShareAdd on Google
Tags: CLDI Viatris Investor Conferences Healthcare Santosh Kesari Scientific Advisory Board interview biopharma
Last updated: Feb 3, 2024

Biotech snapshot

Cash runway
$4M liquidity · $1M/mo burn
~2 mo
High dilution risk